No Relief From Drug Shortages; New Lymphedema Guideline; A ‘Good’ Patient No More

Drug shortages persist, as the FDA faces multiple challenges in its oversight of COVID-19-related production disruptions at foreign manufacturing facilities. (BioSpace)

A wrongful death lawsuit filed in Florida alleges that Intuitive Surgical’s da Vinci robotic surgical system burned and tore the small intestine of a patient during an operation for colon cancer. (NBC News)

An international collaboration of experts has published the first clinical guideline for preventing and managing lymphedema. (eClinicalMedicine)

High rates of re-excision after breast-conserving surgery continue to increase the cost of care and the risk of complications. (UTHealth Houston, Annals of Surgical Oncology)

Many people remain unaware of the hazards of ultraviolet light exposure during the winter, and few people take precautions against sun exposure during outdoor activities in the winter. (American Academy of Dermatology)

Gilead Sciences announced discontinuation of a phase III trial of magrolimab in acute myeloid leukemia because of increased mortality and said the FDA put a clinical hold on all studies of the drug in myelodysplastic syndrome.

The National Comprehensive Cancer Network published its first treatment recommendations for neuroblastoma, the most common type of solid tumor in children aside from brain tumors.

Treating lung cancer with chemoradiotherapy increases patients’ risk of severe infections, and they should receive early intervention with antibiotics, according to a retrospective study from China. (Malignancy Spectrum)

An experimental MYC inhibitor passed an early clinical test, becoming the first drug in the class to demonstrate safety and efficacy in a phase I study. (Vall D’Hebron Institute of Oncology)

Why a person with leukemia decided to stop being a “good” patient. (Time)

Please enable JavaScript to view the

comments powered by Disqus.